We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+9.32%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$871M
AUM Growth
+$56.2M
Cap. Flow
+$80.3M
Cap. Flow %
9.22%
Top 10 Hldgs %
80.56%
Holding
31
New
7
Increased
6
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$56.4M
2
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$47M
3
RXDX
Ignyta, Inc.
RXDX
+$24.3M
4
RDUS
Radius Health, Inc.
RDUS
+$19M
5
AKBA icon
Akebia Therapeutics
AKBA
+$10.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.6M
2
LOXO
Loxo Oncology, Inc
LOXO
+$12.6M
3
ZGNX
Zogenix, Inc.
ZGNX
+$12.3M
4
NGNE icon
Neurogene
NGNE
+$11.3M
5
ARDX icon
Ardelyx
ARDX
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIGR
26
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-11,807
Closed -$4.06M
CALA
27
DELISTED
Calithera Biosciences, Inc
CALA
– –
-36,250
Closed -$8.37M
FOMX
28
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-1,820,138
Closed -$9.01M
BOLD
29
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-532,426
Closed -$9.07M
MDCO
30
DELISTED
Medicines Co
MDCO
– –
-79,899
Closed -$3.91M
LOXO
31
DELISTED
Loxo Oncology, Inc
LOXO
– –
-298,935
Closed -$12.6M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, RA Capital Management held 31 positions worth $871M, up 6.9% from $815M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

RA Capital Management deployed $80.3M of net new capital in Q2 2017, opening 7 new positions and adding to 6 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 2,448,350 shares worth $61.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was AveXis, Inc. Common Stock, an estimated $23.6M trimmed.

  • RA Capital Management's largest Q2 2017 buy was Biohaven Pharmaceutical Holding Company Ltd.: 2,448,350 shares worth $61.2M.
  • RA Capital Management added most to Ignyta, Inc. in Q2 2017, an estimated $24.3M increase.
  • RA Capital Management's biggest Q2 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $23.6M.
  • RA Capital Management fully exited Loxo Oncology, Inc in Q2 2017, selling an estimated $12.6M.
  • RA Capital Management's ten largest holdings make up 81% of its $871M portfolio in Q2 2017.
  • RA Capital Management opened 7 new positions and closed 9 in Q2 2017.
  • RA Capital Management's portfolio value rose 6.9% quarter-over-quarter to $871M.

Based on RA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.